Short Interest in MetaVia Inc. (NASDAQ:MTVA) Decreases By 53.4%

MetaVia Inc. (NASDAQ:MTVA) saw a large decrease in short interest in July. As of July 31st, there was short interest totaling 160,464 shares, a decrease of 53.4% from the July 15th total of 344,566 shares. Approximately 3.1% of the company’s stock are sold short. Based on an average daily trading volume, of 100,346 shares, the days-to-cover ratio is currently 1.6 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent filing with the SEC. 1.37% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MTVA has been the subject of several research reports. Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. Wall Street Zen upgraded MetaVia to a “sell” rating in a research note on Saturday, June 20th. Finally, HC Wainwright reiterated a “buy” rating on shares of MetaVia in a report on Friday, July 10th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $20.00.

MetaVia Price Performance

Shares of MTVA traded up $0.03 during midday trading on Friday, reaching $1.49. The stock had a trading volume of 69,155 shares, compared to its average volume of 91,237. The company’s fifty day simple moving average is $1.60 and its two-hundred day simple moving average is $1.69. MetaVia has a 1-year low of $0.97 and a 1-year high of $19.03.

MetaVia (NASDAQ:MTVA) last issued its earnings results on Thursday, August 6th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.08). Equities analysts forecast that MetaVia will post -2.79 EPS for the current fiscal year.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.